Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
Condition(s):Multiple SclerosisLast Updated:March 19, 2021Completed
Hide Studies Not Open or Pending
Condition(s):Multiple SclerosisLast Updated:March 19, 2021Completed
Condition(s):Acute Decompensated Heart Failure; Cytokine Storm; Inflammatory Response; Heart FailureLast Updated:August 22, 2023Completed
Condition(s):Relapsing Multiple SclerosisLast Updated:June 16, 2021Completed
Condition(s):Cutaneous Squamous Cell Carcinoma; Squamous Cell Carcinoma; Basal Cell CarcinomaLast Updated:May 19, 2023Active, not recruiting
Condition(s):Relapsing-Remitting Multiple SclerosisLast Updated:April 2, 2014Terminated
Condition(s):Multiple SclerosisLast Updated:December 29, 2016Completed
Condition(s):Multiple SclerosisLast Updated:October 8, 2013Completed
Condition(s):Multiple SclerosisLast Updated:December 29, 2023Active, not recruiting
Condition(s):Rett SyndromeLast Updated:November 5, 2018Completed
Condition(s):Multiple SclerosisLast Updated:December 9, 2021Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.